The PennZone

LANGHORNE, Pa. ~ Techdow USA Inc., a vertically integrated generic injectables company, has announced the FDA approval of Enoxaparin Sodium (Preservative Free) in Prefilled Syringes for the U.S. market.

Darren Alkins, Chief Executive Officer of Techdow USA, said "We are excited to bring this critical product to institutions, retail and other networks in need of a safe, affordable and reliable source of Enoxaparin. Our U.S. and global networks will help ensure reliable Enoxaparin supply, while offering competitive pricing."

The launch of Enoxaparin will compliment Techdow USA's existing Heparin Sodium injection business which was launched in 2022. According to IQVIA Health for the 12 months ending December 2022, Enoxaparin Sodium (Preservative Free) Prefilled Syringes had US brand and generic sales of approximately $550 million.

Techdow USA is among the fastest growing companies in the US generic pharmaceutical industry specializing in the sale of generic injectable pharmaceuticals and continues to work to expand their product portfolio and pipeline to better serve patient and customer needs. To report SUSPECTED ADVERSE REACTIONS, contact Hepalink USA, Inc./Techdow USA, Inc. at 1-888-355-1375 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For more information visit www.techdowusa.com.*Lovenox® is a registered trademark of Sanofi-Aventis U.S. LLC

More on The PennZone

• Fourth Annual Free Training Day Mid-Atlantic Returns Sept. 19, 2026
• Las Vegas Headliner Don Barnhart Brings National Touring Comedy Show to Comedy Cabana
• Nevada Boxing Hall of Fame Announces 14th Annual Induction Gala Weekend Honoring Classes of 2025 and 2026
• Brosix Celebrates 20 Years of Private Team Messaging for Small and Mid-Sized Businesses
• Top 15 Mosquito-Infested Cities in Louisiana and East Texas Ranked for 2026 Mosquito Season

Techdow USA Inc., a growing market leader in the generic injectables industry, has announced that its product Enoxaparin Sodium (Preservative Free) in Prefilled Syringes has been approved by the FDA for use in the U.S market. Darren Alkins, Chief Executive Officer of Techdow USA expressed his excitement about bringing this critical product to institutions, retail and other networks that need a safe, affordable and reliable source of Enoxaparin with competitive pricing options available through their U.S and global networks as well as being a long term reliable resource for the marketplace .

The launch of Enoxaparin compliments Techdow USA's existing Heparin Sodium injection business which was launched in 2022 with IQVIA Health reporting US brand and generic sales for this product at approximately $550 million for the 12 months ending December 2022 .

Techdow USA is continuing its efforts to expand its product portfolio and pipeline to better serve patient and customer needs while also being one of the fastest growing companies in the US generic pharmaceutical industry specializing in selling generic injectable pharmaceuticals . To report SUSPECTED ADVERSE REACTIONS contact Hepalink USA , Inc./Techdow USA , Inc . at 1 - 888 - 355 - 1375 or FDA at 1 - 800 - FDA - 1088 or www . fda . gov / medwatch . For more information visit www . techdowusa . com * Lovenox® is a registered trademark of Sanofi - Aventis U . S . LLC

---

Show All News | Disclaimer | Report Violation